Menu

Growing Placenta-Generating Cells

Researchers derive trophoblast stem cells from mouse fibroblasts, paving the way for cell therapy for placental dysfunction diseases.

Oct 14, 2015
Jef Akst

High-magnification micrograph of intermediate trophoblast cellsWIKIMEDIA, NEPHRONTransiently expressing three genes in mouse fibroblasts, an international team of researchers has coaxed the cells into trophoblast stem-like cells (TSCs), skipping a pluripotent stage. The derived cells had similar characteristics to blastocyst-derived TSCs—which form most of the developing placenta—and contributed to placental cell lineages in vitro, according to a study published last month (September 24) in Cell Stem Cell.

“Here, we describe a method to generate stable and fully functional TSC-like cells from murine fibroblasts by transient ectopic expression of three TSC key master regulators, Gata3, Eomes, and Tfap2c,” the authors wrote in their paper. “These data suggest that the conversion of fibroblasts into iTSCs represents a very high degree of nuclear reprogramming and refute the hypothesis that complete nuclear reprogramming can be achieved only in cells undergoing conversion to ESC-like cells.”

“The success of this study will grant a real chance for women who suffer from placental dysfunction diseases to have healthy babies,” according to a press release. When the placenta does not develop properly or is damaged, the baby be born prematurely, have a low birth weight, or have other complications that can risk both the child’s and mother’s health. “To date, tools to model or treat these diseases are limited because all attempts to isolate and propagate the human placenta precursor cells . . . in the dish have failed.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.